These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 20857352)

  • 41. Clinical Trials of Poly(ADP-Ribose) Polymerase Inhibitors for Cancer Therapy: A Review.
    Buege M; Mahajan PB
    Rev Recent Clin Trials; 2015; 10(4):326-39. PubMed ID: 26374559
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Poly(ADP-ribose) polymerase inhibitors in triple-negative breast cancer.
    Comen EA; Robson M
    Cancer J; 2010; 16(1):48-52. PubMed ID: 20164690
    [TBL] [Abstract][Full Text] [Related]  

  • 43. PARP inhibitors: polypharmacology versus selective inhibition.
    Ekblad T; Camaioni E; Schüler H; Macchiarulo A
    FEBS J; 2013 Aug; 280(15):3563-75. PubMed ID: 23601167
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mechanism and current progress of Poly ADP-ribose polymerase (PARP) inhibitors in the treatment of ovarian cancer.
    Zheng F; Zhang Y; Chen S; Weng X; Rao Y; Fang H
    Biomed Pharmacother; 2020 Mar; 123():109661. PubMed ID: 31931287
    [TBL] [Abstract][Full Text] [Related]  

  • 45. PARP-1 inhibitors: a novel genetically specific agents for cancer therapy.
    Cipak L; Jantova S
    Neoplasma; 2010; 57(5):401-5. PubMed ID: 20568893
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Poly(ADP-ribose) polymerase inhibition in cancer therapy: are we close to maturity?
    Papeo G; Forte B; Orsini P; Perrera C; Posteri H; Scolaro A; Montagnoli A
    Expert Opin Ther Pat; 2009 Oct; 19(10):1377-400. PubMed ID: 19743897
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Magnitude of benefit of the addition of poly ADP-ribose polymerase (PARP) inhibitors to therapy for malignant tumor: A meta-analysis.
    Gu L; Du N; Jin Q; Li S; Xie L; Mo J; Shen Z; Mao D; Ji J; Khadaroo PA; Chen B
    Crit Rev Oncol Hematol; 2020 Mar; 147():102888. PubMed ID: 32018126
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Multi-targeted organometallic ruthenium(II)-arene anticancer complexes bearing inhibitors of poly(ADP-ribose) polymerase-1: A strategy to improve cytotoxicity.
    Wang Z; Qian H; Yiu SM; Sun J; Zhu G
    J Inorg Biochem; 2014 Feb; 131():47-55. PubMed ID: 24239912
    [TBL] [Abstract][Full Text] [Related]  

  • 49. PARP inhibitors in breast cancer.
    Telli ML; Ford JM
    Clin Adv Hematol Oncol; 2010 Sep; 8(9):629-35. PubMed ID: 21157412
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [PARP inhibitors: significant progress in cancer therapy].
    Dantzer F; Noel G; Schreiber V
    Bull Cancer; 2011 Mar; 98(3):277-90. PubMed ID: 21459712
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Immunohistochemical detection of poly(ADP-ribose) polymerase inhibition by ABT-888 in patients with refractory solid tumors and lymphomas.
    Yang SX; Kummar S; Steinberg SM; Murgo AJ; Gutierrez M; Rubinstein L; Nguyen D; Kaur G; Chen AP; Giranda VL; Tomaszewski JE; Doroshow JH;
    Cancer Biol Ther; 2009 Nov; 8(21):2004-9. PubMed ID: 19823047
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Poly(ADP-ribose) polymerase inhibitors: new pharmacological functions and potential clinical implications.
    de la Lastra CA; Villegas I; Sánchez-Fidalgo S
    Curr Pharm Des; 2007; 13(9):933-62. PubMed ID: 17430191
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The current status of PARP inhibitors in ovarian cancer.
    McLachlan J; George A; Banerjee S
    Tumori; 2016 Oct; 102(5):433-440. PubMed ID: 27716873
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Poly ADP-ribose polymerase inhibitors: science and current clinical development.
    Liu JF; Silver DP
    Curr Opin Oncol; 2010 Nov; 22(6):567-72. PubMed ID: 20739886
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Poly(ADP-Ribose) Polymerase in Cervical Cancer Pathogenesis: Mechanism and Potential Role for PARP Inhibitors.
    Kotsopoulos IC; Kucukmetin A; Mukhopadhyay A; Lunec J; Curtin NJ
    Int J Gynecol Cancer; 2016 May; 26(4):763-9. PubMed ID: 26905326
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Non-NAD-Like poly(ADP-Ribose) Polymerase-1 Inhibitors effectively Eliminate Cancer in vivo.
    Thomas C; Ji Y; Lodhi N; Kotova E; Pinnola AD; Golovine K; Makhov P; Pechenkina K; Kolenko V; Tulin AV
    EBioMedicine; 2016 Nov; 13():90-98. PubMed ID: 27727003
    [TBL] [Abstract][Full Text] [Related]  

  • 57. How to kill tumor cells with inhibitors of poly(ADP-ribosyl)ation.
    Mangerich A; Bürkle A
    Int J Cancer; 2011 Jan; 128(2):251-65. PubMed ID: 20853319
    [TBL] [Abstract][Full Text] [Related]  

  • 58. PARP inhibitors: A new era of targeted therapy.
    Tangutoori S; Baldwin P; Sridhar S
    Maturitas; 2015 May; 81(1):5-9. PubMed ID: 25708226
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Poly(ADP-ribose) polymerase inhibitor therapeutic effect: are we just scratching the surface?
    Hottiger MO
    Expert Opin Ther Targets; 2015; 19(9):1149-52. PubMed ID: 26212149
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
    Schreiber V; Illuzzi G; Héberlé E; Dantzer F
    Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.